Butyrate

Butyrate at a Glance

Butyrate is the anion (conjugate base) of butyric acid — a four-carbon short-chain fatty acid (SCFA), formula C₄H₇O₂⁻. This page covers both the acid and the anion, plus the supplemental forms sodium butyrate and tributyrin (a butyrate-bearing triglyceride prodrug). At the physiological pH of the gut and blood the acid is almost entirely dissociated, so “butyrate” and “butyric acid” describe the same species in the body.

What makes butyrate one of the most consequential molecules in the whole database is that it is not really a plant constituent at all — it is what your gut bacteria make from plant fibre. When colonic microbes ferment resistant starch, inulin, and gums such as arabinogalactans / gum arabic, the major product is butyrate (alongside acetate and propionate). It is then the primary energy source of the cells lining the colon ^{1,2Reference 1Roediger WEW · 1980Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in manView study →Reference 2Donohoe DR et al. · 2011The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colonView study →}, a histone-deacetylase (HDAC) inhibitor that reprograms gene expression, and a signalling molecule at the receptors GPR43 (FFAR2), GPR41 (FFAR3) and GPR109A (HCAR2) ^{5,7Reference 5Singh N et al. · 2014Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesisView study →Reference 7Canani RB et al. · 2011Potential beneficial effects of butyrate in intestinal and extraintestinal diseasesView study →}. Through those routes it induces regulatory T cells, sets an anti-inflammatory tone in the gut ^{3,4,5Reference 3Furusawa Y et al. · 2013Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cellsView study →Reference 4Arpaia N et al. · 2013Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generationView study →Reference 5Singh N et al. · 2014Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesisView study →}, and strengthens the intestinal barrier ^{6Reference 6Peng L et al. · 2009Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayersView study →}.

Two framings matter before any claim. First, most of butyrate’s demonstrated benefit is from butyrate produced in situ from fibre, not from swallowing the isolate — the strongest human evidence is mechanistic (colonocyte metabolism) and dietary (fibre), while the oral sodium-butyrate / tributyrin supplement trial base is smaller, often uses microencapsulated or combination products, and is still maturing ^{9,10Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →}. Second, butyrate is a genuinely clinically relevant molecule with real human data — so its support scores sit above a trace plant phenol’s — but graded honestly against where the evidence is isolate-and-preclinical versus human.

(A naming note: butyrate / butyric acid is not gamma-hydroxybutyrate (GHB) — a separate, controlled psychoactive compound with a hydroxyl on the fourth carbon. They are chemically and pharmacologically unrelated despite the similar name.)

Where Butyrate Comes From: Fibre, Not Food

The everyday sources of butyrate split cleanly in two, and only one of them matters at scale.

Endogenous (the important one): the colon’s anaerobic bacteria — chiefly Faecalibacterium prausnitzii, Roseburia, Eubacterium and other firmicutes — ferment non-digestible carbohydrate into SCFAs, with butyrate the dominant product in the distal colon. This is where the physiologically meaningful quantities are generated, right at the epithelium that consumes it. Every “fibre is anti-inflammatory / metabolically protective / colon-cancer-protective” story runs largely through this butyrate.
Dietary (minor): butyric acid occurs preformed in butter and dairy fat (~3-4% of milk fat — the source of the name, from Latin butyrum), parmesan and aged cheeses, and ghee. But dietary butyrate is absorbed high in the gut and never reaches the colon in quantity, so it is a flavour and trace-nutrition story, not the source of the colonic effects.
Supplemental: sodium butyrate (usually microencapsulated to survive the stomach and deliver lower down) and tributyrin (a triglyceride of three butyrate units, hydrolysed to release butyrate) are taken to raise butyrate exposure directly — the pragmatic workaround for someone who cannot ferment enough fibre.

This is exactly why butyrate is the mechanistic root of the prebiotic story on herbs like acacia (gum arabic): the fibre itself does little, but the butyrate the colon makes from it carries the anti-inflammatory and metabolic signal ^{11,12Reference 11Al-Jubori Y et al. · 2023Systematic reviewThe efficacy of gum arabic in managing diseases: a systematic review of evidence-based clinical trialsView study →Reference 12Elnour AAM · 2023ReviewGum arabic: an optimization overview of its properties and applications. (review). https://pubmed.ncbi.nlm.nih.gov/37929233/View study →}.

What It's Used For

Butyrate acts through three coupled mechanisms — as a fuel, as an HDAC inhibitor, and as a receptor ligand — and almost every effect below is one of those three read out in a different tissue.

The colon’s main fuel — the best-established fact here:butyrate supplies ~60-70% of the colonic epithelium’s energy, oxidised in preference to glucose ^{1Reference 1Roediger WEW · 1980Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in manView study →}. Deprive colonocytes of it (as in germ-free animals) and they fall into an energy-starved, autophagic state that butyrate alone rescues ^{2Reference 2Donohoe DR et al. · 2011The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colonView study →}. This is human-and-mechanistic, not speculative.

An HDAC inhibitor and immune signal:butyrate inhibits histone deacetylases and signals at GPR43/GPR41/GPR109A, and through these induces colonic regulatory T cells and an anti-inflammatory macrophage/dendritic-cell program ^{3,4,5Reference 3Furusawa Y et al. · 2013Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cellsView study →Reference 4Arpaia N et al. · 2013Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generationView study →Reference 5Singh N et al. · 2014Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesisView study →} — the molecular basis for fibre’s anti-inflammatory tone.

A gut-barrier strengthener:it tightens the epithelial barrier by promoting tight-junction assembly via AMPK ^{6Reference 6Peng L et al. · 2009Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayersView study →}, complementing its role as fuel for the same cells.

Real but early clinical use:oral/rectal butyrate has been trialled in IBD and IBS, often as microencapsulated or combination products, with modest, mixed benefit ^{9,10Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →} — the human supplement evidence is the weakest part of an otherwise strong mechanistic story.

The honest headline:the powerful evidence is for endogenously produced butyrate (i.e. eat fibre); the oral isolate is plausible and lightly supported, not proven, and its systemic (beyond-gut) effects in humans remain largely preclinical.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Butyrate scores higher than a typical plant constituent because it has genuine human-mechanistic and clinical data; scores are still capped where the evidence is the supplement rather than endogenous butyrate, or preclinical. Read the per-row basis.

Mechanisms

Target / pathway	Effect	Relevant to
Mitochondrial β-oxidation (colonocyte fuel)	primary energy substrate (~60-70% of colonic epithelial energy); rescues energy-starvation autophagy	colonocyte energybarrierIBD
Histone deacetylases (HDAC)	inhibition → altered gene expression, Foxp3 acetylation, differentiation/apoptosis in transformed cells	Treg inductionanti-inflammatorycolorectal cancer
GPR109A (HCAR2, niacin/butyrate receptor)	activation → anti-inflammatory macrophages/DCs, Treg + IL-10 induction, IL-18 in epithelium	anti-inflammatoryIBDcolon cancer
GPR43 (FFAR2) / GPR41 (FFAR3)	SCFA sensing → immune modulation, gut-hormone (GLP-1/PYY) release	anti-inflammatorymetabolic/glycaemic
Tight-junction assembly via AMPK	↑ barrier integrity, ↓ permeability	gut barriersystemic inflammation

The load-bearing thread is that one molecule wears three hats — fuel, HDAC inhibitor, receptor ligand — and which hat dominates depends on the cell: fuel in the healthy colonocyte, HDAC inhibitor in the cancer cell (the “butyrate paradox”), and receptor ligand for the immune and metabolic signalling. The Treg/anti-inflammatory and colonocyte-fuel roles are the best-substantiated.

Pharmacokinetics

Butyrate’s pharmacokinetics are dominated by where it is made and where it is consumed. Colonic butyrate is generated at the epithelium and largely taken up and oxidised locally by colonocytes before it ever reaches the portal blood — so luminal concentrations are high (millimolar) while systemic plasma levels stay low. What escapes the colon is heavily extracted by the liver, leaving little for peripheral tissues; this first-pass, local-consumption profile is exactly why endogenous butyrate acts overwhelmingly in and on the gut. Oral butyric acid itself is impractical (rapid upper-GI absorption, plus an infamously rancid, vomit-like odour), which is why supplements use microencapsulated sodium butyrate — engineered to survive the stomach and release lower down — or tributyrin, a triglyceride prodrug that is hydrolysed to free butyrate more distally. Robust human ADME data for these oral forms (how much butyrate actually reaches the colon and blood, and for how long) remain limited, which is a real weakness of the supplement case.

Clinical Trials

Human trials exist — the distinguishing feature versus most constituents here — but they test formulated or combination butyrate for GI conditions, not the pure isolate for systemic disease, and are mostly small.

Completed	Planned	Terminated	Preclinical
Small RCTs of oral/microencapsulated or enema butyrate in IBD ^{9Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →} and IBS (often combination products) ^{10Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →}	Ongoing SCFA/fibre and butyrate-supplement trials	—	Extensive: Treg/HDAC immunology ^{3,4Reference 3Furusawa Y et al. · 2013Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cellsView study →Reference 4Arpaia N et al. · 2013Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generationView study →}, GPR109A ^{5Reference 5Singh N et al. · 2014Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesisView study →}, barrier/AMPK ^{6Reference 6Peng L et al. · 2009Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayersView study →}, colon-cancer and metabolic mechanisms ^{7Reference 7Canani RB et al. · 2011Potential beneficial effects of butyrate in intestinal and extraintestinal diseasesView study →}

Last checked: July 2026.

Isolate vs. Endogenous Butyrate

The split here is unusually important and worth stating plainly, because it inverts the usual “isolate is better studied” pattern. For butyrate, the strongest evidence is for the endogenously produced molecule — colonocyte fuel ^{1,2Reference 1Roediger WEW · 1980Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in manView study →Reference 2Donohoe DR et al. · 2011The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colonView study →}, Treg induction ^{3,4,5Reference 3Furusawa Y et al. · 2013Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cellsView study →Reference 4Arpaia N et al. · 2013Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generationView study →Reference 5Singh N et al. · 2014Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesisView study →}, barrier integrity ^{6Reference 6Peng L et al. · 2009Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayersView study →} — all generated in situ from fibre and acting locally. The isolate as a swallowed supplement is the weaker arm: plausible, mechanistically motivated, lightly and mixedly supported by small human trials in IBD and IBS ^{9,10Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →}, and hampered by delivery problems (odour, upper-GI absorption) that force reliance on microencapsulation or tributyrin prodrugs.

The practical reading: the best-evidenced way to raise your butyrate is to feed the bacteria that make it — a diverse, fibre-rich diet including fermentable substrates like resistant starch, inulin and gum arabic (acacia) ^{11,12Reference 11Al-Jubori Y et al. · 2023Systematic reviewThe efficacy of gum arabic in managing diseases: a systematic review of evidence-based clinical trialsView study →Reference 12Elnour AAM · 2023ReviewGum arabic: an optimization overview of its properties and applications. (review). https://pubmed.ncbi.nlm.nih.gov/37929233/View study →}. Sodium-butyrate and tributyrin supplements are a reasonable, low-risk adjunct where fibre fermentation is inadequate, but they are not a substitute for the endogenous system, and their independent human benefit is not yet firmly established.

Toxicity & Safety

Butyrate carries a low flag. It is a normal, abundant product of human colonic fermentation and a natural component of dairy fat and cheese — the body is built to make and consume it in gram quantities daily, and it is used as a food additive/flavouring and as a widely sold dietary supplement (sodium butyrate, tributyrin) with a good tolerability record. In trials, oral/microencapsulated butyrate is generally well tolerated, the main issues being palatability (odour/taste of unencapsulated forms) and occasional mild GI symptoms ^{9,10Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →}.

The honest limits are those of a lightly regulated supplement rather than of a hazardous compound: large, high-quality long-term safety trials of the oral isolate are lacking, formulations and doses vary widely, and there are no meaningful human drug-interaction data. A theoretical nuance worth noting is the “butyrate paradox” context — butyrate is protective for normal colon tissue but is a bioactive HDAC inhibitor, so its behaviour is cell-context-dependent; at dietary and ordinary supplemental exposures this is a point of biological interest, not a safety concern. As always, concentrated supplements in pregnancy, lactation or active disease are best used under professional guidance.

Safety at a Glance

Low / no toxicity

A natural, abundant human metabolite. Made in gram quantities daily by your own colon and present in butter and cheese; used as a food additive and generally recognised as low-risk.
Well tolerated in trials. Oral/microencapsulated and enema butyrate are broadly well tolerated in IBD and IBS studies, with mostly mild GI effects ^{9,10Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →}.
Supplement safety data are thin. No large, long-term trials of the oral isolate; doses and formulations vary and human interaction data are essentially absent.
Context-dependent bioactivity. Butyrate is an HDAC inhibitor whose effects depend on cell type (the “butyrate paradox”); a biological nuance, not a dietary-level hazard.

Dosage

There is no established therapeutic dose of isolated butyrate, and nothing here is a recommendation. The most evidence-backed “dose” is indirect: eat enough fermentable fibre for your colonic bacteria to make butyrate — the mechanism behind fibre-, resistant-starch- and gum-arabic-based approaches.

Application	Form / route (research)	Dose studied
Colonic fuel / general gut health	Dietary fibre (fibre → colonic butyrate)	Not a fixed dose; a fibre-rich diet — the best-evidenced route ^{1,2Reference 1Roediger WEW · 1980Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in manView study →Reference 2Donohoe DR et al. · 2011The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colonView study →}
IBS	Microencapsulated sodium butyrate (often + probiotics/FOS)	~150-600 mg/day over ~12 weeks, in combination products ^{10Reference 10Gąsiorowska A et al. · 2024RCTEfficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled studyView study →}
IBD	Oral (microencapsulated) or butyrate enema	Oral trials in the hundreds-of-mg/day range; enemas use higher local doses ^{9Reference 9Facchin S et al. · 2026RCTImpact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiotaView study →}

Human exposure is otherwise dietary (butter, cheese, ghee) and, dominantly, endogenous. Supplemental sodium butyrate and tributyrin are low-risk but modestly evidenced; the doses above are research doses, not personal advice.

References

Roediger WEW (1980). Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut. https://pubmed.ncbi.nlm.nih.gov/7429343/
Donohoe DR, Garge N, Zhang X, et al. (2011). The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/21531334/
Furusawa Y, Obata Y, Fukuda S, et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. https://pubmed.ncbi.nlm.nih.gov/24226770/
Arpaia N, Campbell C, Fan X, et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature. https://pubmed.ncbi.nlm.nih.gov/24226773/
Singh N, Gurav A, Sivaprakasam S, et al. (2014). Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity. https://pubmed.ncbi.nlm.nih.gov/24412617/
Peng L, Li ZR, Green RS, Holzman IR, Lin J (2009). Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. The Journal of Nutrition. https://pubmed.ncbi.nlm.nih.gov/19625695/
Canani RB, Costanzo MD, Leone L, et al. (2011). Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World Journal of Gastroenterology. https://pubmed.ncbi.nlm.nih.gov/21472114/
Mohamed Elfadil O, Mundi MS, Abdelmagid MG, et al. (2023). Butyrate: more than a short chain fatty acid. Current Nutrition Reports. https://pubmed.ncbi.nlm.nih.gov/36763294/
Facchin S, Calgaro M, Pandolfo M, et al. (2026). Impact of oral butyrate on clinical and biochemical parameters in IBD: a randomized placebo-controlled study targeting gut microbiota. Digestive and Liver Disease. https://pubmed.ncbi.nlm.nih.gov/41354580/
Gąsiorowska A, Romanowski M, Walecka-Kapica E, et al. (2024). Efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics, and short-chain fructooligosaccharides in patients with irritable bowel syndrome — a randomized, double-blind, placebo-controlled study. Journal of Clinical Medicine. https://pubmed.ncbi.nlm.nih.gov/39797089/
Al-Jubori Y, Ahmed NTB, Albusaidi R, et al. (2023). The efficacy of gum arabic in managing diseases: a systematic review of evidence-based clinical trials. Biomolecules. https://pubmed.ncbi.nlm.nih.gov/36671523/
Elnour AAM, Abdurahman NH (2023). Gum arabic: an optimization overview of its properties and applications. (review). https://pubmed.ncbi.nlm.nih.gov/37929233/